<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> arises as the consequence of mutations and epigenetic alterations that activate oncogenes and inactivate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes </plain></SENT>
<SENT sid="1" pm="."><plain>Through a genome-wide screen for methylated genes in colon <z:hpo ids='HP_0002664'>neoplasms</z:hpo>, we identified aberrantly methylated RET in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>RET, a transmembrane receptor tyrosine kinase and a receptor for the glial cell-derived neurotrophic factor family ligands, was one of the first oncogenes to be identified, and has been shown to be an oncogene in <z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">thyroid cancer</z:e> and <z:hpo ids='HP_0002666'>pheochromocytoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, unexpectedly, we found RET is methylated in 27% of colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> and in 63% of <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, and now provide evidence that RET has <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor activity in <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The aberrant methylation of RET correlates with decreased RET expression, whereas the restoration of RET in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines results in <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, in support of a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor function of RET, mutant RET has also been found in primary <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We now show that these mutations inactivate RET, which is consistent with RET being a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene in the colon </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that the aberrant methylation of RET and the mutational inactivation of RET promote <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> formation, and that RET can serve as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene in the colon </plain></SENT>
<SENT sid="8" pm="."><plain>Moreover, the increased frequency of methylated RET in <z:hpo ids='HP_0003003'>colon cancers</z:hpo> compared with <z:mpath ids='MPATH_270'>adenomas</z:mpath> suggests RET inactivation is involved in the progression of colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>.Oncogene advance online publication, 2 July 2012; doi:10.1038/onc.2012.225 </plain></SENT>
</text></document>